Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04221204 · ClinicalTrials.gov registry record · Phase 1
A Monotherapy in Subjects With Advanced Solid Tumors
A Phase 1 study of Solid Tumor, Adult, sponsored by 3D Medicines (Beijing) Co..
- Active
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 2
- Study locations
NCT04221204: Active Phase 1 study of Solid Tumor, Adult, sponsored by 3D Medicines (Beijing) Co..
NCT04221204 is a Phase 1 study of Solid Tumor, Adult that is active but no longer recruiting, run by 3D Medicines (Beijing) Co.. The registered enrollment target is 42 participants, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04221204, a Phase 1 study of Solid Tumor, Adult, is active but no longer recruiting, sponsored by 3D Medicines (Beijing) Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 2
- Study locations
Study Summary
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics Profiles, and Preliminary Efficacy of 3D185 Monotherapy in Subjects with Advanced Solid Tumors
Primary Outcome
Evaluated based on the frequency and severity of AEs according to NCI CTCAE v4.03.
Conditions Studied
Interventions
- DRUG Highly selective FGFR1-3 inhibitor
Study Locations (2)
California
- Sarcoma Oncolog Research Center - Santa Monica
Other
- Shanghai East Hospital - Shanghai
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 1 |
What the registry record for NCT04221204 still lists
NCT04221204 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 1 intervention - of which Highly selective FGFR1-3 inhibitor is the first listed.
NCT04221204 reports a single indexed study location in California, Other.
Frequently Asked Questions
What is clinical trial NCT04221204 about?
NCT04221204 is a clinical study titled "A Monotherapy in Subjects With Advanced Solid Tumors". A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics Profiles, and Preliminary Efficacy of 3D185 Monotherapy in Subjects with Advanced Solid Tumors
What is the current status of trial NCT04221204?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2019-09-01. Estimated completion is 2026-12-30.
What conditions does trial NCT04221204 study?
This clinical trial studies the following conditions: Solid Tumor, Adult.
What interventions are being tested in trial NCT04221204?
The interventions under investigation include: Highly selective FGFR1-3 inhibitor (DRUG).
Who is sponsoring clinical trial NCT04221204?
This trial is sponsored by 3D Medicines (Beijing) Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04221204 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04221204's enrollment target sits among peer trials
42 64th of 72 higher than 9 of 72 other Solid Tumor, Adult trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor, Adult trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI